Welcome to our dedicated page for Teleflex news (Ticker: TFX), a resource for investors and traders seeking the latest updates and insights on Teleflex stock.
Teleflex Inc (NYSE: TFX) is a global medical technology leader developing devices that enhance patient care across surgical, interventional, and critical care settings. This news hub provides investors and healthcare professionals with timely updates on TFX's clinical advancements, regulatory milestones, and strategic initiatives.
Access authoritative reporting on product innovations like the UroLift system, vascular access solutions, and anesthesia devices that demonstrate Teleflex's commitment to evidence-based medicine. Our curated news collection covers essential developments including quarterly earnings, FDA clearances, partnership announcements, and clinical trial outcomes.
Key updates focus on Teleflex's core therapeutic areas: minimally invasive surgical tools, critical care devices, and urology solutions. Stay informed about technologies improving procedural safety and healthcare economics through verified press releases and objective analysis.
Bookmark this page for consolidated access to Teleflex's latest progress in medical device innovation, financial performance data, and market expansion efforts. Regularly updated to serve as your primary resource for understanding TFX's role in advancing global medical standards.
Teleflex (NYSE: TFX) has received Health Canada approval for the MANTA® Vascular Closure Device, marking a significant regulatory milestone. This device is designed for large bore femoral arterial access site closure and enhances the availability of innovative solutions for Canadian clinicians. Since its launch in 2016, over 100,000 patients have been treated with the MANTA® Device worldwide. The SAFE MANTA IDE Clinical Trial demonstrated the device's effectiveness in achieving rapid hemostasis without the need for pre-closure, enabling quicker and safer procedures.
Teleflex Incorporated (NYSE: TFX) announced the U.S. launch of its UroLift® 2 System and UroLift ATC® System for treating benign prostatic hyperplasia (BPH). These advancements were showcased at the 2022 American Urological Association (AUA) annual meeting in New Orleans from May 13-16. The UroLift 2 offers an ergonomic design and improved workflow, while the UroLift ATC enhances treatment options for patients with obstructive middle lobes. Teleflex will host a special presentation on these innovations at booth #323 during the event.
Teleflex will host an Analyst & Investor Day on May 20, 2022, in New York City. The event features presentations from CEO Liam Kelly and the leadership team, starting at 10:00 a.m. ET. Key agenda items include discussions on durable growth, growth drivers, and financial objectives for 2023-2025. Following the presentations, there will be live breakout sessions. The webcast will be available on the company’s website after the event.
Teleflex (NYSE: TFX) announced a quarterly cash dividend of $0.34 per share, payable on June 15, 2022, to shareholders of record by the close of business on May 16, 2022. As a global provider of medical technologies, Teleflex focuses on innovations to improve healthcare outcomes across various fields, including vascular access and anesthesia. This dividend reflects the company's commitment to returning value to shareholders while continuing its mission to meet clinical needs effectively.
Teleflex (NYSE: TFX) reported Q1 2022 revenues of $641.7 million, showing a 1.2% year-over-year increase. GAAP diluted EPS rose to $1.63 from $1.58 in the prior year. The company reiterated its 2022 GAAP revenue growth guidance of 2.3% to 3.8% and adjusted diluted EPS guidance of $13.70 to $14.30. Segment performance varied, with the Americas growing 0.7%, EMEA declining 3.1%, and Asia increasing by 8.6%. Teleflex acknowledged ongoing inflation and supply chain challenges but remains optimistic about its growth potential.
Teleflex Incorporated (NYSE: TFX) will feature its Chairman and CEO, Liam Kelly, at the Bank of America Securities 2022 Healthcare Conference. The event takes place on May 10, 2022, at 11:20 a.m. (PT) in Las Vegas. A live audio webcast of the presentation will be accessible on the investor section of the Teleflex website.
Teleflex Incorporated (NYSE:TFX) announced a conference call scheduled for 8:00 a.m. Eastern Time on April 28, 2022, to discuss its first quarter 2022 results and provide an operational update. Interested participants can register through a specified link, and a replay of the call will be available starting at 11:00 a.m. on the same day. Teleflex focuses on innovative medical technologies across various fields, including vascular access and anesthesia, aimed at improving health outcomes.
Teleflex Incorporated (NYSE: TFX) has launched the UroLift System in Japan, addressing benign prostatic hyperplasia (BPH). This minimally invasive treatment offers quick symptom relief and allows patients to resume normal activities while preserving sexual function. With prior reimbursement approval from the Central Social Insurance Medical Council of Japan, the system is now commercially available. Teleflex aims to make the UroLift System the standard of care for BPH globally, marking a significant step in its overseas expansion strategy.
Teleflex's CFO, Thomas Powell, will present at the KeyBanc Life Sciences & MedTech Investor Forum on March 23, 2022, at 9:45 a.m. (ET). Investors can access a live audio webcast of the presentation on the Teleflex website. The company is a global provider of medical technologies, focusing on enhancing health and quality of life through innovative solutions in various medical fields. Teleflex is recognized for its trusted brands, including Arrow®, QuikClot®, and LMA®.
Teleflex Incorporated (NYSE: TFX) will feature its Chairman, President, and CEO, Liam Kelly, at the 43rd Annual Raymond James Institutional Investors Conference. The event will be held on March 8, 2022, at 9:15 a.m. ET in Orlando, FL. A live audio webcast and accompanying slide presentation will be accessible on Teleflex's investor website. As a leading provider of medical technologies, Teleflex aims to improve health and quality of life through innovative solutions across various fields such as vascular access, anesthesia, and emergency medicine.
FAQ
What is the current stock price of Teleflex (TFX)?
What is the market cap of Teleflex (TFX)?
